Results 11 to 20 of about 7,825,369 (248)

Primary progressive multiple sclerosis in the Polish population

Aktualności Neurologiczne, 2017
Objectives: The aim of the study was the epidemiological analysis and evaluation of selected clinical and sociodemographic factors in Polish patients with primary progressive multiple sclerosis.
Waldemar Brola, Piotr Sobolewski, Stanisław Flaga, Małgorzata Fudala, Andrzej Potemkowski   +4 more
doaj   +2 more sources

Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence

Patient Preference and Adherence, 2022
Sajida Sabsabi,1 Elio Mikhael,2 Georges Jalkh,1 Gabrielle Macaron,1,3 Mary Rensel3 1Department of Neurology, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon; 2Department of Internal Medicine, Hotel Dieu de France Hospital, Saint ...
Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M   +4 more
doaj   +2 more sources

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
El Ayoubi NK, Al Ghazal S, Hannoun S, Siddik MA, Najjar NM, Dagher J, Abboud J, Semaan MG, Khoury SJ.   +8 more
europepmc   +2 more sources

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. [PDF]

Brain, 2023
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand'Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Castillo-Triviño T, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T.   +91 more
europepmc   +2 more sources

Disease Course After Anti-CD20 Discontinuation in Secondary Progressive Multiple Sclerosis-A Multicenter Long-Term Longitudinal Study. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Otto F, Kliushnikova D, Radlberger RF, Yasaroglu S, Moser T, Harrer A, Kratzer K, Hitzl W, Gradl C, Schmidauer M, Roth P, Hegen H, Wipfler P.   +12 more
europepmc   +2 more sources

Comparison of medical and social characteristics and quality of life of patients with primary- and secondary-progressive multiple sclerosis

Неврология, нейропсихиатрия, психосоматика, 2021
Management of patients with secondary progressive multiple sclerosis (SPMS) remains one of the most challenging tasks of modern neurology. Patients with SPMS present with more severe neurological symptoms, increased hospitalization frequency, pronounced ...
Ya. V. Vlasov, N. G. Polyarnaya, A. N. Boyko   +2 more
doaj   +1 more source

Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment

Frontiers in Neurology, 2022
Multiple sclerosis is a progressive demyelinating central nervous system disorder with unknown etiology. The condition has heterogeneous presentations, including relapsing-remitting multiple sclerosis and secondary and primary progressive multiple ...
Sundararajan Jayaraman, Arathi Jayaraman
doaj   +1 more source

Advances in clinical diagnosis of secondary progressive multiple sclerosis [PDF]

Zhenduanxue lilun yu shijian, 2022
Multiple sclerosis(MS) is a chronic inflammatory disease of the central nervous system that involves demyelination and axonal degeneration. Usually, MS begins with a relapsing-remitting MS (RRMS) course, and approxi mately will develop into secondary ...
ZHANG Chao, GAO Xue
doaj   +1 more source

Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil

BMC Neurology, 2022
Background Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS), which is a chronic neurological disease, characterised by inflammation of the central nervous system.
Vijayalakshmi Vasanthaprasad, Vivek Khurana, Sreelatha Vadapalle, Jackie Palace, Nicholas Adlard   +4 more
doaj   +1 more source

External validation of a clinical prediction model in multiple sclerosis [PDF]

, 2023
Background: Timely initiation of disease modifying therapy is crucial for managing multiple sclerosis (MS). Objective: We aimed to validate a previously published predictive model of individual treatment response using a non-overlapping cohort from the ...
Inshasi, Jihad, Malpas, Charles B, Yamout, Bassem I., Altıntaş, Ayşe, Yamout, Bassem, Türkoǧlu, Recai, Sharmin, Sifat, Shalaby, Nevin Mohieldin, Karabudak, Rana, Al-Harbi, Talal, Shalaby, Nevin, Shaygannejad, Vahid, Khoury, Samia J., Khoury, Samia J, Boz, Cavit, Soysal, Aysun, Alroughani, Raed, Inshasi, Jihad Said, Terzi, Murat, Moradi, Nahid, Malpas, Charles B., Alroughani, Raed A., Al-Harbi, Talal M., Kalincik, Tomas, Altintaş, Ayşe   +24 more
core   +1 more source